Definium Therapeutics pioneers psychedelic therapies, focusing on anxiety and addiction treatments with promising clinical trials.
ATAI
ATAI Life Sciences invests in multiple psychedelic startups aiming to revolutionize mental health care.
CYBIN
Cybin focuses on creating novel psychedelic compounds with enhanced safety profiles for therapy.
COMPASS PATHWAYS
Compass Pathways is in the late stages of the regulatory process, with positive Phase 3 clinical trial results for their proprietary psilocybin therapy, COMP360, for treatment-resistant depression. They are actively working toward a commercial launch.
Dive into psychedelic stock insights and connect with our community ! (Discord coming soon.)
